Amedeo Smart

Free Medical Literature Service


 

Amedeo

Liver Diseases

  Free Subscription

Articles published in
Semin Liver Dis
    May 2024
  1. BALOGUN O, Nejak-Bowen K
    Understanding Hepatic Porphyrias: Symptoms, Treatments, and Unmet Needs.
    Semin Liver Dis. 2024 May 17. doi: 10.1055/s-0044-1787076.
    >> Share

  2. MA J, Bjornsson ES, Chalasani N
    Hepatotoxicity of Antibiotics and Antifungals and Their Safe Use in Hepatic Impairment.
    Semin Liver Dis. 2024 May 13. doi: 10.1055/s-0044-1787062.
    >> Share

    April 2024
  3. SAVIANO A, Roehlen N, Baumert TF
    Tight Junction Proteins as Therapeutic Targets to Treat Liver Fibrosis and Hepatocellular Carcinoma.
    Semin Liver Dis. 2024 Apr 22. doi: 10.1055/s-0044-1785646.
    >> Share

    March 2024
  4. KODAMA T, Takehara T
    Molecular genealogy of metabolic-associated hepatocellular carcinoma.
    Semin Liver Dis. 2024 Mar 18. doi: 10.1055/a-2289-2298.
    >> Share

    February 2024
  5. ROMERO-GOMEZ M, Arab JP, Oliveira CP, Hernandez M, et al
    Is There a Safe Alcohol Consumption Limit for the General Population and in Patients with Liver Disease?
    Semin Liver Dis. 2024;44:69-78.
    >> Share

  6. CANIVET CM, Boursier J, Loomba R
    New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice.
    Semin Liver Dis. 2024;44:35-42.
    >> Share

  7. MOUZAKI M, Woo JG, Divanovic S
    Gestational and Developmental Contributors of Pediatric MASLD.
    Semin Liver Dis. 2024;44:43-53.
    >> Share

  8. TUTUSAUS A, Morales A, Garcia de Frutos P, Mari M, et al
    GAS6/TAM Axis as Therapeutic Target in Liver Diseases.
    Semin Liver Dis. 2024;44:99-114.
    >> Share

  9. BESSONE F, Hillotte GL, Ahumada N, Jaureguizahar F, et al
    UDCA for Drug-Induced Liver Disease: Clinical and Pathophysiological Basis.
    Semin Liver Dis. 2024;44:1-22.
    >> Share

  10. EL-KASSAS M, Awad A, Elbadry M, Arab JP, et al
    Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Semin Liver Dis. 2024;44:54-68.
    >> Share

  11. BECH KT, Lindvig KP, Thiele M, Castera L, et al
    Algorithms for Early Detection of Silent Liver Fibrosis in the Primary Care Setting.
    Semin Liver Dis. 2024;44:23-34.
    >> Share

  12. LIU H, Sethi V, Li X, Xiao Y, et al
    Corrigendum: Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future.
    Semin Liver Dis. 2024;44:e1-e3.
    >> Share

    January 2024
  13. LIU H, Sethi V, Li X, Xiao Y, et al
    Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future.
    Semin Liver Dis. 2024 Jan 11. doi: 10.1055/a-2242-7543.
    >> Share

    November 2023
  14. BALOGUN O, Nejak-Bowen K
    The Hepatic Porphyrias: Revealing the Complexities of a Rare Disease.
    Semin Liver Dis. 2023 Nov 16. doi: 10.1055/s-0043-1776760.
    >> Share

  15. WILSON SR, Duncan AW
    The Ploidy State as a Determinant of Hepatocyte Proliferation.
    Semin Liver Dis. 2023 Nov 15. doi: 10.1055/a-2211-2144.
    >> Share

  16. HAN X, Sun Q, Xu M, Zhu G, et al
    Unraveling the Complexities of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Semin Liver Dis. 2023 Nov 6. doi: 10.1055/s-0043-1776127.
    >> Share

  17. SAEIDINEJAD M, Elshabrawi A, Sriphoosanaphan S, Andreola F, et al
    Novel Therapeutic Approaches in Treatment of Acute-on-Chronic Liver Failure.
    Semin Liver Dis. 2023;43:429-445.
    >> Share

  18. DUTTA RK, Jun J, Du K, Diehl AM, et al
    Hedgehog Signaling: Implications in Liver Pathophysiology.
    Semin Liver Dis. 2023;43:418-428.
    >> Share

    August 2023
  19. PEKARSKA K, Parker R
    Alcohol-Related Liver Disease: Is There a Safe Alcohol Consumption Limit for Liver Disease?
    Semin Liver Dis. 2023;43:305-310.
    >> Share

  20. RANJBARIAN T, Schnabl B
    Gut Microbiome-Centered Therapies for Alcohol-Associated Liver Disease.
    Semin Liver Dis. 2023;43:311-322.
    >> Share

  21. DESHMUKH K, Apte U
    The Role of Endoplasmic Reticulum Stress Response in Liver Regeneration.
    Semin Liver Dis. 2023;43:279-292.
    >> Share

  22. MEADOWS V, Yang Z, Basaly V, Guo GL, et al
    FXR Friend-ChIPs in the Enterohepatic System.
    Semin Liver Dis. 2023;43:267-278.
    >> Share

  23. COOPER SA, Kostallari E, Shah VH
    Angiocrine Signaling in Sinusoidal Health and Disease.
    Semin Liver Dis. 2023;43:245-257.
    >> Share

  24. RUIZ M, Lacaille F, Schrader C, Pons M, et al
    Pediatric and Adult Liver Disease in Alpha-1 Antitrypsin Deficiency.
    Semin Liver Dis. 2023;43:258-266.
    >> Share

    May 2023
  25. KOTULKAR M, Robarts D, Apte U
    HNF4-alpha in hepatocyte health and disease.
    Semin Liver Dis. 2023 May 22. doi: 10.1055/a-2097-0660.
    >> Share

  26. VANDERSCHUEREN E, Trebicka J, Laleman W
    Endoscopic Advances in Hepatology.
    Semin Liver Dis. 2023 May 16. doi: 10.1055/s-0043-1769009.
    >> Share

  27. ADORI M, Bhat S, Gramignoli R, Valladolid-Acebes I, et al
    Hepatic Innervations and Nonalcoholic Fatty Liver Disease.
    Semin Liver Dis. 2023 May 8. doi: 10.1055/s-0043-57237.
    >> Share

  28. GOLABI P, Shah D, Younossi ZM
    How to Identify Advanced Nonalcoholic Fatty Liver Disease in the Primary Care Setting.
    Semin Liver Dis. 2023;43:142-148.
    >> Share

  29. REVERTER E, Toapanta D, Bassegoda O, Zapatero J, et al
    Critical Care Management of Acute-on-Chronic Liver Failure: Certainties and Unknowns.
    Semin Liver Dis. 2023;43:206-217.
    >> Share

  30. GU W, Kimmann M, Laleman W, Praktiknjo M, et al
    To TIPS or Not to TIPS in High Risk of Variceal Rebleeding and Acute-on-Chronic Liver Failure.
    Semin Liver Dis. 2023;43:189-205.
    >> Share

  31. BERNARD JK, Marakovits C, Smith LG, Francis H, et al
    Mast Cell and Innate Immune Cell Communication in Cholestatic Liver Disease.
    Semin Liver Dis. 2023;43:226-233.
    >> Share

  32. SINGH S, Kumar PVSNK, Kumar JP, Tomo S, et al
    Genetic and Epigenetic Basis of Drug-Induced Liver Injury.
    Semin Liver Dis. 2023;43:163-175.
    >> Share

  33. URIAS E, Chen VL
    Screening for At-Risk Nonalcoholic Fatty Liver Disease in the Primary Care Setting.
    Semin Liver Dis. 2023;43:133-141.
    >> Share

    February 2023
  34. KIM M, Rizvi F, Shin D, Gouon-Evans V, et al
    Update on Hepatobiliary Plasticity.
    Semin Liver Dis. 2023 Feb 10. doi: 10.1055/s-0042-1760306.
    >> Share

  35. KELTY TJ, Dashek RJ, Arnold WD, Rector RS, et al
    Emerging Links between Nonalcoholic Fatty Liver Disease and Neurodegeneration.
    Semin Liver Dis. 2023;43:77-88.
    >> Share

  36. OXLEY M, Francis H, Sato K
    Growth Hormone Signaling in Liver Diseases: Therapeutic Potentials and Controversies.
    Semin Liver Dis. 2023;43:24-30.
    >> Share

  37. CHOLANKERIL G, El-Serag HB
    Current Challenges and Future Direction in Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
    Semin Liver Dis. 2023;43:89-99.
    >> Share

    January 2023
  38. SMITH TN, Gallo De Moraes A, Simonetto DA
    Cirrhosis management in the Intensive Care Unit.
    Semin Liver Dis. 2023 Jan 18. doi: 10.1055/a-2015-1290.
    >> Share

    December 2022
  39. BANC-HUSU AM, Shiau H, Dike P, Shneider BL, et al
    Beyond Varices: Complications of Cirrhotic Portal Hypertension in Pediatrics.
    Semin Liver Dis. 2022 Dec 26. doi: 10.1055/s-0042-1759613.
    >> Share

  40. LITTLE A, Medford A, O'Brien A, Childs J, et al
    Recent Advances in Intrahepatic Biliary Epithelial Heterogeneity.
    Semin Liver Dis. 2022 Dec 15. doi: 10.1055/s-0042-1758833.
    >> Share

    November 2022
  41. ROMERO-GOMEZ M, Aller R, Martin-Bermudo F
    Dietary Recommendations for the Management of Non-alcoholic Fatty Liver Disease (NAFLD): A Nutritional Geometry Perspective.
    Semin Liver Dis. 2022;42:434-445.
    >> Share

  42. CHEN B, Tang WHW, Rodriguez M, Corey KE, et al
    NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity?
    Semin Liver Dis. 2022;42:465-474.
    >> Share

  43. PARK Y, Thadasina D, Bolujo I, Isidan A, et al
    Three-Dimensional Organoids as a Model to Study Nonalcoholic Fatty Liver Disease.
    Semin Liver Dis. 2022;42:423-433.
    >> Share

  44. MOTOMURA T, Faccioli LAP, Diaz-Aragon R, Kocas-Kilicarslan ZN, et al
    From a Single Cell to a Whole Human Liver: Disease Modeling and Transplantation.
    Semin Liver Dis. 2022;42:413-422.
    >> Share

  45. HUANG DQ, Downes M, Evans RM, Witztum JL, et al
    Shared Mechanisms between Cardiovascular Disease and NAFLD.
    Semin Liver Dis. 2022;42:455-464.
    >> Share

    October 2022
  46. JUANOLA A, Ma AT, Pose E, Gines P, et al
    Novel biomarkers of AKI in cirrhosis.
    Semin Liver Dis. 2022 Oct 3. doi: 10.1055/a-1954-4136.
    >> Share

    September 2022
  47. GALA K, Abdul Razzak F, Rapaka B, Dayyeh Bk A, et al
    Novel Endoscopic Bariatric Therapies for the Management of Non-Alcoholic Steatohepatitis.
    Semin Liver Dis. 2022 Sep 18. doi: 10.1055/a-1946-6285.
    >> Share

  48. GOFTON C, Agar M, George J
    Early Implementation of Palliative and Supportive Care in Hepatocellular Carcinoma.
    Semin Liver Dis. 2022 Sep 17. doi: 10.1055/a-1946-5592.
    >> Share

  49. RASHA F, Paul S, Simon TG, Hoshida Y, et al
    Hepatocellular carcinoma chemoprevention with generic agents.
    Semin Liver Dis. 2022 Sep 14. doi: 10.1055/a-1942-6693.
    >> Share

    August 2022
  50. TUJIOS S, Stravitz RT, Lee WM
    Management of Acute Liver Failure: Update 2022.
    Semin Liver Dis. 2022;42:362-378.
    >> Share

  51. CARVALHO-GONTIJO R, Han C, Zhang L, Zhang V, et al
    Metabolic Injury of Hepatocytes Promotes Progression of NAFLD and AALD.
    Semin Liver Dis. 2022;42:233-249.
    >> Share

  52. CASTERA L, Boursier J
    Noninvasive Algorithms for the Case Finding of "At-Risk" Patients with NAFLD.
    Semin Liver Dis. 2022;42:313-326.
    >> Share

  53. EL-KASSAS M, Cabezas J, Coz PI, Zheng MH, et al
    Nonalcoholic Fatty Liver Disease: Current Global Burden.
    Semin Liver Dis. 2022;42:401-412.
    >> Share

  54. ATIF J, Thoeni C, Bader GD, McGilvray ID, et al
    Unraveling the Complexity of Liver Disease One Cell at a Time.
    Semin Liver Dis. 2022;42:250-270.
    >> Share

  55. NEVENS F, van der Merwe S
    Mesenchymal Stem Cell Transplantation in Liver Diseases.
    Semin Liver Dis. 2022;42:283-292.
    >> Share

    June 2022
  56. GARCIA-SAENZ-DE-SICILIA M, Al-Obaid L, Hughes DL, Duarte-Rojo A, et al
    Mastering core recommendations during HEPAtology ROUNDS in advanced chronic liver disease.
    Semin Liver Dis. 2022 Jun 28. doi: 10.1055/a-1886-5909.
    >> Share

  57. CHEW N, Ng CH, Truong E, Noureddin M, et al
    Non-Alcoholic Steatohepatitis Drug Development Pipeline: An Update.
    Semin Liver Dis. 2022 Jun 16. doi: 10.1055/a-1877-9656.
    >> Share

  58. KULKARNI AV, Premkumar M, Arab JP, Kumar K, et al
    EARLY DIAGNOSIS AND PREVENTION OF INFECTIONS IN CIRRHOSIS.
    Semin Liver Dis. 2022 Jun 7. doi: 10.1055/a-1869-7607.
    >> Share

    May 2022
  59. GRINSPAN LT, Villanueva A
    Biomarker Development Using Liquid Biopsy in Hepatocellular Carcinoma.
    Semin Liver Dis. 2022;42:188-201.
    >> Share

  60. YUAN WZ, Fu T
    Liver Dysfunction in COVID-19: From Onset to Recovery.
    Semin Liver Dis. 2022;42:151-158.
    >> Share

  61. GUPTA B, Rai R, Oertel M, Raeman R, et al
    Intestinal Barrier Dysfunction in Fatty Liver Disease: Roles of Microbiota, Mucosal Immune System, and Bile Acids.
    Semin Liver Dis. 2022;42:122-137.
    >> Share

  62. TARLI C, Mirijello A, Addolorato G
    Treating Alcohol Use Disorder in Patients with Alcohol-Associated Liver Disease: Controversies in Pharmacological Therapy.
    Semin Liver Dis. 2022;42:138-150.
    >> Share

  63. FASULLO M, Shah T, Zhou H, Siddiqui MS, et al
    Post-Transplant Biliary Strictures: An Updated Review.
    Semin Liver Dis. 2022;42:225-232.
    >> Share

  64. CARROLL HK, Duffy AG, O'Farrelly C
    Liver Immunology, Immunotherapy, and Liver Cancers: Time for a Rethink?
    Semin Liver Dis. 2022;42:212-224.
    >> Share

    February 2022
  65. GALLAHER CE, Shawcross DL
    Management of multidrug-resistant infections in cirrhosis.
    Semin Liver Dis. 2022 Feb 7. doi: 10.1055/a-1765-0056.
    >> Share

  66. PANDAY R, Monckton CP, Khetani SR
    The Role of Liver Zonation in Physiology, Regeneration, and Disease.
    Semin Liver Dis. 2022;42:1-16.
    >> Share

  67. CADAMURO M, Lasagni A, Sarcognato S, Guido M, et al
    The Neglected Role of Bile Duct Epithelial Cells in NASH.
    Semin Liver Dis. 2022;42:34-47.
    >> Share

  68. TERZI E, Ayuso C, Piscaglia F, Bruix J, et al
    Liver Imaging Reporting and Data System: Review of Pros and Cons.
    Semin Liver Dis. 2022;42:104-111.
    >> Share

    November 2021
  69. TELLEZ L, Rodriguez de Santiago E, Albillos A
    Fontan-Associated Liver Disease: Pathophysiology, Staging, and Management.
    Semin Liver Dis. 2021;41:538-550.
    >> Share

  70. RADUN R, Trauner M
    Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities.
    Semin Liver Dis. 2021;41:461-475.
    >> Share

  71. MAIWALL R, Sarin SK
    Plasma Exchange in Acute and Acute on Chronic Liver Failure.
    Semin Liver Dis. 2021;41:476-494.
    >> Share

  72. GU X, Lu Q, Zhang C, Tang Z, et al
    Clinical Application and Progress of Fecal Microbiota Transplantation in Liver Diseases: A Review.
    Semin Liver Dis. 2021;41:495-506.
    >> Share

  73. MENDOZA YP, Becchetti C, Watt KD, Berzigotti A, et al
    Risks and Rewards of Bariatric Surgery in Advanced Chronic Liver Diseases.
    Semin Liver Dis. 2021;41:448-460.
    >> Share

  74. HASHEM A, Khalouf A, Acosta A
    Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review.
    Semin Liver Dis. 2021;41:435-447.
    >> Share

  75. ARRESE M, Arab JP, Barrera F, Kaufmann B, et al
    Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity.
    Semin Liver Dis. 2021;41:421-434.
    >> Share

  76. KOHUT TJ, Gilbert MA, Loomes KM
    Alagille Syndrome: A Focused Review on Clinical Features, Genetics, and Treatment.
    Semin Liver Dis. 2021;41:525-537.
    >> Share

  77. LI N, Yamamoto G, Fuji H, Kisseleva T, et al
    Interleukin-17 in Liver Disease Pathogenesis.
    Semin Liver Dis. 2021;41:507-515.
    >> Share

    October 2021
  78. JENG WJ, Liaw YF
    Erratum to: Finite Antiviral Therapy in Chronic Hepatitis B Patients with Cirrhosis.
    Semin Liver Dis. 2021 Oct 1. doi: 10.1055/s-0041-1737024.
    >> Share

    September 2021
  79. MARIN JJG, Romero MR, Herraez E, Asensio M, et al
    Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems.
    Semin Liver Dis. 2021 Sep 20. doi: 10.1055/s-0041-1735631.
    >> Share

    August 2021
  80. SHERMAN M
    Assessing Toxicity in Drug Trials in Liver Disease.
    Semin Liver Dis. 2021;41:277-284.
    >> Share

  81. KAWAGUCHI T, Charlton M, Kawaguchi A, Yamamura S, et al
    Effects of Mediterranean Diet in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials.
    Semin Liver Dis. 2021;41:225-234.
    >> Share

  82. ZELBER-SAGI S
    Dietary Treatment for NAFLD: New Clinical and Epidemiological Evidence and Updated Recommendations.
    Semin Liver Dis. 2021;41:248-262.
    >> Share

  83. NILLES KM, Levitsky J
    Current and Evolving Indications for Simultaneous Liver Kidney Transplantation.
    Semin Liver Dis. 2021;41:308-320.
    >> Share

  84. MA L, Khatib S, Craig AJ, Wang XW, et al
    Toward a Liver Cell Atlas: Understanding Liver Biology in Health and Disease at Single-Cell Resolution.
    Semin Liver Dis. 2021;41:321-330.
    >> Share

  85. MOLLER S, Kimer N, Kronborg T, Grandt J, et al
    Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms.
    Semin Liver Dis. 2021;41:235-247.
    >> Share

  86. ENGELMANN C, Martino VD, Kerbert AJC, Weil-Verhoeven D, et al
    The Current Status of Granulocyte-Colony Stimulating Factor to Treat Acute-on-Chronic Liver Failure.
    Semin Liver Dis. 2021;41:298-307.
    >> Share

    July 2021
  87. VAZ K, Goodwin T, Kemp W, Roberts S, et al
    Artificial Intelligence in Hepatology: A Narrative Review.
    Semin Liver Dis. 2021 Jul 29. doi: 10.1055/s-0041-1731706.
    >> Share

  88. ZHOU Y, Tao J, Calvisi DF, Chen X, et al
    Role of Lipogenesis Rewiring in Hepatocellular Carcinoma.
    Semin Liver Dis. 2021 Jul 26. doi: 10.1055/s-0041-1731709.
    >> Share

  89. KAHL S, Putzer J, Roden M
    Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis.
    Semin Liver Dis. 2021 Jul 21. doi: 10.1055/s-0041-1732354.
    >> Share

    June 2021
  90. JENG WJ, Liaw YF
    Finite Antiviral Therapy in Chronic Hepatitis B Patients with Cirrhosis.
    Semin Liver Dis. 2021 Jun 28. doi: 10.1055/s-0041-1729973.
    >> Share

  91. HSU YC, Tseng CH, Huang YT, Yang HI, et al
    Application of Risk Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: Current Status and Future Perspective.
    Semin Liver Dis. 2021 Jun 23. doi: 10.1055/s-0041-1730924.
    >> Share

  92. BRESSON-HADNI S, Spahr L, Chappuis F
    Hepatic Alveolar Echinococcosis.
    Semin Liver Dis. 2021 Jun 23. doi: 10.1055/s-0041-1730925.
    >> Share

  93. SU YY, Li CC, Lin YJ, Hsu C, et al
    Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives.
    Semin Liver Dis. 2021 Jun 15. doi: 10.1055/s-0041-1730949.
    >> Share

    May 2021
  94. HAEP N, Florentino RM, Squires JE, Bell A, et al
    The Inside-Out of End-Stage Liver Disease: Hepatocytes are the Keystone.
    Semin Liver Dis. 2021 May 15. doi: 10.1055/s-0041-1725023.
    >> Share

  95. USON JUNIOR PLS, Nagalo BM, Ahn DH, Bekaii-Saab T, et al
    Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?
    Semin Liver Dis. 2021 May 6. doi: 10.1055/s-0040-1722646.
    >> Share

  96. MOECKLI B, Majno P, Orci LA, Peloso A, et al
    Liver Transplantation Selection and Allocation Criteria for Hepatocellular Carcinoma: A European Perspective.
    Semin Liver Dis. 2021 May 6. doi: 10.1055/s-0041-1723032.
    >> Share

  97. SEKIBA K, Otsuka M, Koike K
    Potential of HBx Gene for Hepatocarcinogenesis in Noncirrhotic Liver.
    Semin Liver Dis. 2021 May 6. doi: 10.1055/s-0041-1723033.
    >> Share

  98. GIL-GOMEZ A, Brescia P, Rescigno M, Romero-Gomez M, et al
    Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers.
    Semin Liver Dis. 2021;41:191-205.
    >> Share

  99. ORTIZ V, Ellenberg SS, Weinberg EM
    Blinding in Clinical Trials for Chronic Liver Diseases.
    Semin Liver Dis. 2021;41:163-171.
    >> Share

  100. DUNN MA, Kappus MR, Bloomer PM, Duarte-Rojo A, et al
    Wearables, Physical Activity, and Exercise Testing in Liver Disease.
    Semin Liver Dis. 2021;41:128-135.
    >> Share

    January 2021
  101. HARTMANN P, Schnabl B
    New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease.
    Semin Liver Dis. 2021;41:87-102.
    >> Share

  102. FERREIRA-GONZALEZ S, Rodrigo-Torres D, Gadd VL, Forbes SJ, et al
    Cellular Senescence in Liver Disease and Regeneration.
    Semin Liver Dis. 2021;41:50-66.
    >> Share

  103. WANG H, Calvisi DF, Chen X
    Organoids for the Study of Liver Cancer.
    Semin Liver Dis. 2021;41:19-27.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016